Lung cancer is the leading cause of cancer related death in the United States killing over 130,000 people each year. While a combination of chemo and radiation therapy may be effective, surgery is still required for many patients. Without surgery, the disease may progress and lead to metastases. We sought to determine if treatment with anti-non-muscle myosin IIA antibody would inhibit movement of the cells in the presence and absence of glabridin (an isoflavonoid compound shown to inhibit cell migration by inhibiting myosin). We compared inhibition by glabridin to that of an anti-non-muscle myosin IIA antibody and a combination therapy of both at 12 and 24 hours post wound creation. Cells that took up the anti-non-muscle myosin IIA antibody were greatly inhibited in motility and exhibited no significant change in wound healing. Glabridin treatment resulted in a dramatic increase in wound size within 12 hours and regeneration within 24 hours. The greatest decrease in motility was observed in cells treated with the combination of both glabridin and anti-non-muscle myosin IIA antibody. By 24 hrs, cell migration had halted due to death of the cells resulting from this combination. Further testing needs to be done to determine a safe mode of delivery of the combination therapy to ensure only local distribution. Controlled release drug delivery depot systems have been used as a means to provide local release of drugs intra-tumorally or adjacent to the cancerous tissue after surgical resection and have great potential.
References
[1]
Lu, T., Yang, X., Huang, Y., et al. (2019) Trends in the Incidence, Treatment, and Survival of Patients with Lung Cancer in the Last Four Decades. Cancer Management and Research, 11, 943-953. https://doi.org/10.2147/CMAR.S187317
[2]
Zappa, C. and Mousa, S.A. (2016) Non-Small Cell Lung Cancer: Current Treatment and Future Advances. Translational Lung Cancer Research, 5, 288-300. https://doi.org/10.21037/tlcr.2016.06.07
[3]
Lemjabbar-Alaoui, H., Hassan, O.U., Yang, Y.W., et al. (2015) Lung Cancer: Biology and Treatment Options. Biochimica et Biophysica Acta, 1856, 189-210. https://doi.org/10.1016/j.bbcan.2015.08.002
[4]
DelaCruz, C.S., Tanoue, L.T. and Matthay, R.A. (2011) Lung Cancer: Epidemiology, Etiology, and Prevention. Clinics in Chest Medicine, 32, 605-644. https://doi.org/10.1016/j.ccm.2011.09.001
[5]
Molina, J.R., Yang, P., Cassivi, S.D., et al. (2008) Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic Proceedings, 83, 584-594. https://doi.org/10.1016/S0025-6196(11)60735-0
[6]
Pezzuto, A., D’Ascanio, M., Ricci, A., et al. (2020) Expression and Role of p16 and GLUT1 in Malignant Diseases and Lung Cancer: A Review. Thoracic Cancer, 11, 3060-3070. https://doi.org/10.1111/1759-7714.13651
[7]
Uramoto, H. and Tanaka, F. (2014) Recurrence after Surgery in Patients with NSCLC. Translational Lung Cancer Research, 3, 242-249.
[8]
National Collaborating Centre for Cancer (UK) (2011) The Diagnosis and Treatment of Lung Cancer (Update). National Collaborating Centre for Cancer (UK), Cardiff.
[9]
Semenza, G.L. (2003) Targeting HIF-1 for Cancer Therapy. Nature Reviews Cancer, 3, 721-732. https://doi.org/10.1038/nrc1187
[10]
Pezzuto, A., Perrone, G., Orlando, N., et al. (2019) A Close Relationship between HIF-1α Expression and Bone Metastases in Advanced NSCLC, a Retrospective Analysis. Oncotarget, 10, 7071-7079. https://doi.org/10.18632/oncotarget.27378
[11]
Jiang, Y., Chen, M., Nie, H. and Yuan, Y. (2019) PD-1 and PD-L1 in Cancer Immunotherapy: Clinical Implications and Future Considerations. Human Vaccines & Immunotherapeutics, 15, 1111-1122. https://doi.org/10.1080/21645515.2019.1571892
[12]
Redin, E., Garmendia, I., Lozano, T., et al. (2021) SRC Family Kinase (SFK) Inhibitor Dasatinib Improves the Antitumor Activity of Anti-PD-1 in NSCLC Models by Inhibiting Treg Cell Conversion and Proliferation. Journal for ImmunoTherapy of Cancer, 9, e001496. https://doi.org/10.1136/jitc-2020-001496
[13]
Vokes, E.E. and Chu, E. (2006) Anti-EGFR Therapies: Clinical Experience in Colorectal, Lung, and Head and Neck Cancers. Oncology, 20, 15-25.
[14]
Zhu, K., Li, K., Wang, H., et al. (2019) Discovery of Glabridin as Potent Inhibitor of Epidermal Growth Factor Receptor in SK-BR-3 Cell. Pharmacology, 104, 113-125. https://doi.org/10.1159/000496798
[15]
Hsu, Y.L., Wu, L.Y., Hou, M.F., et al. (2011) Glabridin, an Isoflavan from Licorice Root, Inhibits Migration, Invasion and Angiogenesis of MDA-MB-231 Human Breast Adenocarcinoma Cells by Inhibiting Focal Adhesion Kinase/Rho Signaling Pathway. Molecular Nutrition & Food Research, 55, 318-327. https://doi.org/10.1002/mnfr.201000148
[16]
Tsai, Y.M., Yang, C.J., Hsu, Y.L., et al. (2011) Glabridin Inhibits Migration, Invasion, and Angiogenesis of Human Non-Small Cell Lung Cancer A549 Cells by Inhibiting the FAK/Rho Signaling Pathway. Integrative Cancer Therapies, 10, 341-349. https://doi.org/10.1177/1534735410384860
[17]
Katoh, K. (2017) Activation of Rho-Kinase and Focal Adhesion Kinase Regulates the Organization of Stress Fibers and Focal Adhesions in the Central Part of Fibroblasts. PeerJ, 5, e4063. https://doi.org/10.7717/peerj.4063
[18]
Dobbins, K.R. and Saul, R.F. (2000) Transient Visual Loss after Licorice Ingestion. Journal of Neuro-Ophthalmology, 20, 38-41. https://doi.org/10.1097/00041327-200020010-00013
[19]
Goel, B., Sharma, A., Tripathi, N., et al. (2020) In-Vitro Antitumor Activity of Compounds from Glycyrrhiza glabra against C6 Glioma Cancer Cells: Identification of Natural Lead for Further Evaluation. Natural Product Research, 1, 1-4. https://doi.org/10.1080/14786419.2020.1786830
[20]
Huttenlocher, A. and Horwitz, A.R. (2011) Integrins in Cell Migration. Cold Spring Harbor Perspectives in Biology, 3, a005074. https://doi.org/10.1101/cshperspect.a005074
[21]
Parsons, J.T., Horwitz, A.R. and Schwartz, M.A. (2010) Cell Adhesion: Integrating Cytoskeletal Dynamics and Cellular Tension. Nature Reviews Molecular Cell Biology, 11, 633-643. https://doi.org/10.1038/nrm2957
[22]
Vicente-Manzanares, M., Ma, X., Adelstein, R.S., et al. (2009) Non-Muscle Myosin II Takes Centre Stage in Cell Adhesion and Migration. Nature Reviews Molecular Cell Biology, 10, 778-790. https://doi.org/10.1038/nrm2786
[23]
Conti, M.A. and Adelstein, R.S. (2008) Nonmuscle Myosin II Moves in New Directions. Journal of Cell Science, 121, 11-18. https://doi.org/10.1242/jcs.007112
[24]
Stewart, S.A., Domínguez-Robles, J., Donnelly, R.F., et al. (2018) Implantable Polymeric Drug Delivery Devices: Classification, Manufacture, Materials, and Clinical Applications. Polymers-Basel, 10, 1379. https://doi.org/10.3390/polym10121379
[25]
Wolinsky, J.B., Colson, Y.L. and Grinstaff, M.W. (2012) Local Drug Delivery Strategies for Cancer Treatment: Gels, Nanoparticles, Polymeric Films, Rods, and Wafers. Journal of Controlled Release, 159, 14-26. https://doi.org/10.1016/j.jconrel.2011.11.031
[26]
DeSouza, R., Zahedi, P., Allen, C.J., et al. (2010) Polymeric Drug Delivery Systems for Localized Cancer Chemotherapy. Drug Delivery, 17, 365-375. https://doi.org/10.3109/10717541003762854
